Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 14/20 | 0.57 |
| ▸ | ITGA2B | P08514 | 14/20 | 0.57 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.48 |
| ▸ | ITGAV | P06756 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 6/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 6/20 | 0.44 |
| ▸ | F10 | P00742 | 4/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7238070 | 0.98 | ITGB3 (0.54) | ITGB3ITGA2BGRM2ITGAVCHRM2 | |
| SCHEMBL7228211 | 0.97 | ITGB3 (0.54) | ITGB3ITGA2BGRM2ITGAVCHRM2 | |
| SCHEMBL7229085 | 0.97 | ITGB3 (0.54) | ITGB3ITGA2BGRM2ITGAVCHRM2 | |
| SCHEMBL3267949 | 0.95 | ITGB3 (0.51) | ITGB3ITGA2BGRM2ITGAVCHRM2 | |
| SCHEMBL7236076 | 0.94 | ITGB3 (0.50) | ITGB3ITGA2BGRM2ITGAVCHRM2 | |
| SCHEMBL3266803 | 0.93 | GRM2 (0.52) | ITGB3ITGA2BGRM2PRSS1PRSS2 | |
| SCHEMBL6032832 | 0.93 | ITGB3 (0.56) | ITGB3ITGA2BGRM2ITGAVCHRM2 | |
| SCHEMBL7238569 | 0.91 | ITGB3 (0.52) | ITGB3ITGA2BGRM2ITGAVCHRM2 | |
| SCHEMBL7229618 | 0.89 | GRM2 (0.50) | ITGB3ITGA2BGRM2PRSS1PRSS2 | |
| SCHEMBL7238492 | 0.87 | ITGB3 (0.50) | ITGB3ITGA2BGRM2PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6602876-B1 | Adhesion receptor antagonists | MERCK PATENT GMBH (DE) | 2003-08-05 | — | — | US | claimed |
| EP-0710657-B1 | Antagonists of adhesion receptors | MERCK PATENT GMBH (DE) | 1998-08-26 | — | — | EP | claimed |
| EP-0710657-A1 | Antagonists of adhesion receptors | MERCK PATENT GmbH (DE) | 1996-05-08 | — | — | EP | claimed |
| EP-0951295-B1 | COMPOSITIONS FOR USE IN INHIBITING OF ALPHA-V-BETA3 MEDIATED ANGIOGENESIS | SCRIPPS RESEARCH INST (US) | 2010-06-09 | — | — | EP | disclosed |
| US-20060270710-A1 | Methods for inhibition of angiogenesis | THE SCRIPPS RESEARCH INSTITUTE | 2006-11-30 | — | — | US | disclosed |
| US-20060165703-A1 | Methods and compositions useful for inhibition of alpha v beta 5 mediated angiogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-07-27 | — | — | US | disclosed |
| US-7053041-B1 | Methods and compositions useful for inhibition of αvβ5mediated angiogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1613268-A2 | METHODS FOR INHIBITION OF ANGIOGENESIS | The Scripps Research Institute (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087057-A2 | METHODS FOR INHIBITION OF ANGIOGENESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004087057-A2 | METHODS FOR INHIBITION OF ANGIOGENESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-10-14 | — | — | WO | disclosed |
| US-20040063790-A1 | Methods for inhibition of angiogenesis | THE SCRIPPS RESEARCH INSTITUTE | 2004-04-01 | — | — | US | disclosed |
| EP-0907661-A1 | METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF alpha v beta 5 MEDIATED ANGIOGENESIS | The Scripps Research Institute (US) | 1999-04-14 | — | — | EP | disclosed |
| EP-0710657-B1 | Antagonists of adhesion receptors | MERCK PATENT GMBH (DE) | 1998-08-26 | — | — | EP | disclosed |
| EP-0844874-A1 | METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF $g(a) v?$g(b) 5? MEDIATED ANGIOGENESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-06-03 | — | — | EP | disclosed |
| WO-1997045447-A9 | METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF αvβ5 MEDIATED ANGIOGENESIS | — | 1998-03-12 | — | — | WO | disclosed |
| WO-1997045137-A1 | METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF ANGIOGENESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1997-12-04 | — | — | WO | disclosed |
| WO-1997045447-A1 | METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF αvβ5 MEDIATED ANGIOGENESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1997-12-04 | — | — | WO | disclosed |
| WO-1997006791-A9 | METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF αvβ5 MEDIATED ANGIOGENESIS | — | 1997-04-03 | — | — | WO | disclosed |
| WO-1997006791-A1 | METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF αvβ5 MEDIATED ANGIOGENESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1997-02-27 | — | — | WO | disclosed |
| EP-0710657-A1 | Antagonists of adhesion receptors | MERCK PATENT GmbH (DE) | 1996-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063790-A1 | Methods for inhibition of angiogenesis | FLT4, ANXA3, VCAM1 | ITGB3 79/4885ITGA2B 1413/4885GRM2 1818/4885 |
| US-20060165703-A1 | Methods and compositions useful for inhibition of alpha v beta 5 mediated angiogenesis | ITGA5, ITGB5, ITGAV | ITGB3 11/4885ITGA2B 21/4885GRM2 3382/4885 |
| US-20060270710-A1 | Methods for inhibition of angiogenesis | FLT4, KDR, FLT1 | ITGB3 5/4885ITGA2B 71/4885GRM2 2267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.